IRIS
UCCELLI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 37.461
AS - Asia 4.681
NA - Nord America 2.574
SA - Sud America 370
AF - Africa 96
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 45.196
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 36.717
US - Stati Uniti d'America 2.399
SG - Singapore 1.974
CN - Cina 1.194
VN - Vietnam 853
FR - Francia 287
BR - Brasile 228
HK - Hong Kong 182
BD - Bangladesh 126
DE - Germania 86
FI - Finlandia 82
CA - Canada 75
AR - Argentina 67
GB - Regno Unito 63
MX - Messico 55
IN - India 53
JP - Giappone 48
CH - Svizzera 39
IQ - Iraq 37
ID - Indonesia 33
NL - Olanda 30
PK - Pakistan 25
ZA - Sudafrica 23
EC - Ecuador 20
RU - Federazione Russa 20
UA - Ucraina 17
JM - Giamaica 16
ES - Italia 15
IE - Irlanda 15
MA - Marocco 15
PH - Filippine 15
SA - Arabia Saudita 14
TR - Turchia 14
VE - Venezuela 14
CO - Colombia 13
KE - Kenya 13
PL - Polonia 12
AZ - Azerbaigian 11
DZ - Algeria 11
UZ - Uzbekistan 11
JO - Giordania 10
TH - Thailandia 10
CL - Cile 9
KR - Corea 9
PY - Paraguay 9
SE - Svezia 9
TW - Taiwan 9
AU - Australia 8
TN - Tunisia 8
BE - Belgio 7
CR - Costa Rica 7
EG - Egitto 7
RS - Serbia 7
AT - Austria 6
IL - Israele 6
LT - Lituania 6
MY - Malesia 6
NI - Nicaragua 6
PT - Portogallo 6
SI - Slovenia 6
GR - Grecia 5
PE - Perù 5
BH - Bahrain 4
BY - Bielorussia 4
KG - Kirghizistan 4
KZ - Kazakistan 4
MN - Mongolia 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
DK - Danimarca 3
GT - Guatemala 3
HR - Croazia 3
IR - Iran 3
SK - Slovacchia (Repubblica Slovacca) 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
HN - Honduras 2
HT - Haiti 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MD - Moldavia 2
MM - Myanmar 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
SN - Senegal 2
SX - ???statistics.table.value.countryCode.SX??? 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
YT - Mayotte 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BZ - Belize 1
Totale 45.168
Salva come PNG Salva come JPEG
Città #
Genova 19.862
Genoa 10.885
Rapallo 2.878
Vado Ligure 2.571
Singapore 976
San Jose 818
Ho Chi Minh City 285
Lauterbourg 269
Ashburn 268
Beijing 228
Hong Kong 170
Hanoi 168
New York 128
Council Bluffs 90
Bordighera 86
Helsinki 78
Frankfurt am Main 70
Santa Clara 63
Los Angeles 46
Haiphong 44
Rome 44
Tokyo 42
Da Nang 40
Milan 38
Mexico City 36
Buffalo 32
St Louis 31
Zurich 30
Orem 25
Montreal 24
São Paulo 24
Chicago 23
Tianjin 23
Atlanta 19
Hải Dương 18
Southampton 16
Baghdad 15
Dublin 14
Johannesburg 13
Nairobi 13
Toronto 13
Amsterdam 12
Des Moines 12
Phủ Lý 12
Baku 11
Can Tho 11
Dallas 11
Guangzhou 11
Kingston 11
Naples 11
Phoenix 11
Thái Bình 11
City of London 10
Denver 10
Madrid 10
Ninh Bình 10
Tashkent 10
Amman 9
Bologna 9
Florence 9
Houston 9
Karachi 9
Brescia 8
Chennai 8
Jakarta 8
Kyiv 8
Mumbai 8
Quảng Ngãi 8
Reggio Emilia 8
Stockholm 8
Turin 8
Vĩnh Long 8
Brooklyn 7
Changsha 7
London 7
Memphis 7
Quito 7
Bangkok 6
Istanbul 6
Ljubljana 6
Piscataway 6
Rio de Janeiro 6
San Francisco 6
Santiago 6
Shanghai 6
Sydney 6
Thái Nguyên 6
Asunción 5
Bari 5
Belgrade 5
Bắc Giang 5
Bắc Ninh 5
Cairo 5
Cao Lanh 5
Caracas 5
Casablanca 5
Charlotte 5
Columbus 5
Curitiba 5
Jeddah 5
Totale 40.975
Salva come PNG Salva come JPEG
Nome #
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. 278
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 262
Finger motor performance as a new quantitative clinical endpoint in multiple sclerosis 240
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 237
Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. 235
17p11.2 duplication is a common finding in sporadic cases of charcot-marie-tooth type 1 234
Blood-Brain Barrier Alterations in the Cerebral Cortex in Experimental Autoimmune Encephalomyelitis. 233
Adult stem cells for spinal cord injury: what types and how do they work? 226
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. 218
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 218
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. 217
Neuroprotective features of mesenchymal stem cells. 216
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 214
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 214
CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice 213
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 207
IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways 207
Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis. 206
Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation 203
Quantitative 3D investigation of Neuronal network in mouse spinal cord model 203
Different MRI patterns in MS worsening after stopping fingolimod 203
Unveiling the enigma of the CNS as a B-cell fostering environment. 200
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 200
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 199
A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. 199
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. 198
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. 197
Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. 196
Sirt6 regulates dendritic cell differentiation, maturation, and function 195
Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration 193
Hereditary motor and sensory neuropathy with myelin outfolding: clinical, genetic and neuropathological study of three cases 191
Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ 191
A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. 189
Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD+ release and P2Y11-mediated signaling. 189
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. 189
Ghost spasticity in multiple sclerosis 189
Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. 187
Immunotherapy for neurological diseases. 187
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. 187
Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. 185
Analisi e studio longitudinale della fine specificità di linee linfocitarie T specifiche per la proteina basica della mielina (MBP) in pazienti con sclerosi multipla e in controlli normali. 184
Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis 184
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 184
The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. 184
A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study 183
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 182
Anti-Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia 182
Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. 181
X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model 180
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 180
Investigation of paroxysmal dystonia in a patient with multiple sclerosis: a transcranial magnetic stimulation study. 179
Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks 178
Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1 178
Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS. 178
NG2, a common denominator for neuroinflammation, blood-brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation 177
Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. 176
Characterization of mouse spinal cord vascular network by means of synchrotron radiation X-ray phase contrast tomography 176
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 176
Demyelination and axonal damage in a non-human primate model of multiple sclerosis. 175
Neurorepair with mesenchymal stem cells: hope or hype? 175
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. 175
Teriflunomide treatment reduces B cells in patients with MS. 175
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. 175
Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. 173
Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. 172
Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis 172
The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms 172
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. 172
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. 171
Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? 171
18f-fluorodeoxyglucose positron emission tomography tracks the heterogeneous brain susceptibility to the hyperglycemia-related redox stress 171
Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. 170
A case of thyroiditis during natalizumab therapy for multiple sclerosis 170
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. 170
Hypothalamic AgRP neurons control hematopoiesis and lymphopoiesis and are activated in experimental MS 169
Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. 169
Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. 169
Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. 169
A bridge between evidence-based laboratory diagnostics and research in neuroimmunology: why standardizations and guidelines matter. 169
Central and peripheral nervous system complications following allogeneic bone marrow transplantation. 168
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. 167
Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? 167
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. 166
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 165
CSF oligoclonal bands and normal appearing white matter periventricular damage in patients with clinically isolated syndrome suggestive of MS 165
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 165
T-cell trafficking in the central nervous system. 164
Human mesenchymal stem cells promote survival of T cells in a quiescent state. 164
Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration 162
Primary varicella zoster infection associated with fingolimod treatment. 161
Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. 161
Human mesenchymal stem cells modulate B-cell functions. 160
Stem cells for multiple sclerosis: promises and reality. 159
Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. 159
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 159
Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of “black holes” 159
Catastrophic NAD+ Depletion through Nampt Inhibition in Activated T Lymphocytes Reduces Demyelination and Disability in EAE. 158
Intravenous Mesenchymal Stem Cells Improve Survival and Motor Function in Experimental Amyotrophic Lateral Sclerosis 158
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 157
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS 157
Totale 18.592
Salva come PNG Salva come JPEG
Categoria #
all - tutte 145.666
article - articoli 127.684
book - libri 478
conference - conferenze 13.106
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.398
Totale 291.332
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021341 0 0 0 0 0 0 0 0 0 0 169 172
2021/20223.469 107 213 319 457 152 193 143 755 174 317 118 521
2022/20233.468 329 292 41 362 558 581 21 221 593 37 362 71
2023/20242.391 110 246 70 274 181 405 239 158 126 71 147 364
2024/20257.029 339 480 212 467 811 685 729 1.261 296 361 612 776
2025/202612.682 1.617 428 800 1.156 1.825 958 1.933 771 997 1.347 850 0
Totale 45.942